DECR1抗体;DECR1 Antibody—艾普蒂

The DECR1 (2.4-dienoyl-CoA reductase 1) antibody targets an enzyme critical in mitochondrial fatty acid β-oxidation, specifically involved in metabolizing unsaturated fatty acids. DECR1 catalyzes the reduction of 2.4-dienoyl-CoA to 3-enoyl-CoA, a rate-limiting step in breaking down polyunsaturated fatty acids (PUFAs) with double bonds at even-numbered positions. This enzyme is essential for energy production and lipid homeostasis, particularly in tissues with high metabolic demands like the liver, heart, and skeletal muscle. Dysregulation of DECR1 has been linked to metabolic disorders, neurodegenerative diseases, and cancer, where altered lipid metabolism influences disease progression. The DECR1 antibody is widely used in research to study its expression, localization, and function in cellular and animal models. It enables detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Commercial DECR1 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides, with validation in specific applications. Recent studies highlight its potential role in cancer cell survival under metabolic stress, making it a biomarker of interest for therapeutic targeting. Understanding DECR1’s molecular mechanisms remains vital for exploring its implications in metabolic health and disease.